{
    "Trade/Device Name(s)": [
        "NucliSENS EasyQ System",
        "NucliSENS EasyQ Analyzer",
        "NucliSENS EasyQ Director Software 2.6",
        "NucliSENS EasyQ assay protocol software",
        "NucliSENS EasyQ Incubator II",
        "NucliSENS EasyQ Computer and peripherals",
        "NucliSENS miniMAG"
    ],
    "Submitter Information": "BIOM\u00c9RIEUX",
    "510(k) Number": "K093383",
    "Predicate Device Reference 510(k) Number(s)": [
        "K082562",
        "K063261"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OOI"
    ],
    "Summary Letter Date": "June 23, 2010",
    "Summary Letter Received Date": "June 28, 2010",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.2570"
    ],
    "Regulation Name(s)": [
        "Instrumentation for clinical multiplex test systems"
    ],
    "Analyte Class(es)": [
        "genetic molecular"
    ],
    "Analyte(s)": [],
    "Specimen Type(s)": [],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "NucliSENS EasyQ Analyzer",
        "NucliSENS EasyQ Incubator II",
        "NucliSENS miniMAG",
        "NucliSENS EasyQ Computer and peripherals"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time nucleic acid amplification",
        "Fluorescence detection",
        "Molecular beacon probe binding"
    ],
    "Methodologies": [
        "Automated fluorescence analysis",
        "Nucleic acid amplification detection"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Software",
        "Instrument",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for BIOM\u00c9RIEUX NucliSENS EasyQ System, an automated real-time nucleic acid amplification and fluorescence detection platform with upgraded software and instrumentation.",
    "Indications for Use Summary": "The NucliSENS EasyQ Analyzer and Director software are intended for in vitro diagnostic use with FDA-cleared or approved NucliSENS assay protocols, measuring fluorescent signals from molecular beacon probes bound to amplified RNA or DNA in samples.",
    "fda_folder": "Clinical Chemistry"
}